Author

Lior Kramarski

Weizmann Institute of Science

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

An Nhien TruongiD· 1 shared Arturo Simoni NievesiD· 1 shared Ashish NoronhaiD· 1 shared Boobash-Raj Selvadurai· 1 shared Christopher CherryiD· 1 shared Deepthi Ramesh-KumariD· 1 shared Eviatar WeizmaniD· 1 shared Furkan OzmeniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

An Nhien TruongORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

Rishita Chatterjee, Arturo Simoni Nieves, An Nhien Truong, Moshit Lindzen, Furkan Ozmen, Christopher Cherry, Pascale Zwicky, Saptaparna Mukherjee, Boobash-Raj Selvadurai, Tomer Meir Salame, Nitin Gupta, Suvendu Giri, Lior Kramarski, Yahel Avraham, Eviatar Weizman, , Yosef Yarden

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

bioRxiv · Jun 23, 2025 · PreprintCancer Biology